KR102388028B9 - 폴리펩타이드 전달용 조성물 - Google Patents

폴리펩타이드 전달용 조성물

Info

Publication number
KR102388028B9
KR102388028B9 KR1020190093193A KR20190093193A KR102388028B9 KR 102388028 B9 KR102388028 B9 KR 102388028B9 KR 1020190093193 A KR1020190093193 A KR 1020190093193A KR 20190093193 A KR20190093193 A KR 20190093193A KR 102388028 B9 KR102388028 B9 KR 102388028B9
Authority
KR
South Korea
Prior art keywords
polypptide
delivering
composition
Prior art date
Application number
KR1020190093193A
Other languages
English (en)
Other versions
KR102388028B1 (ko
KR20200014708A (ko
Inventor
원철희
Original Assignee
주식회사 레모넥스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 레모넥스 filed Critical 주식회사 레모넥스
Priority to PCT/KR2019/009564 priority Critical patent/WO2020027585A2/ko
Priority to US17/264,944 priority patent/US20210309763A1/en
Publication of KR20200014708A publication Critical patent/KR20200014708A/ko
Application granted granted Critical
Publication of KR102388028B1 publication Critical patent/KR102388028B1/ko
Publication of KR102388028B9 publication Critical patent/KR102388028B9/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/14—Peptides being immobilised on, or in, an inorganic carrier
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1758—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Nanotechnology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Ceramic Engineering (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
KR1020190093193A 2018-07-31 2019-07-31 폴리펩타이드 전달용 조성물 KR102388028B1 (ko)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/KR2019/009564 WO2020027585A2 (ko) 2018-07-31 2019-07-31 폴리펩타이드 전달용 조성물
US17/264,944 US20210309763A1 (en) 2018-07-31 2019-07-31 Polypeptide delivery composition

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862712323P 2018-07-31 2018-07-31
US62/712,323 2018-07-31

Publications (3)

Publication Number Publication Date
KR20200014708A KR20200014708A (ko) 2020-02-11
KR102388028B1 KR102388028B1 (ko) 2022-04-20
KR102388028B9 true KR102388028B9 (ko) 2023-04-17

Family

ID=69569091

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020190093193A KR102388028B1 (ko) 2018-07-31 2019-07-31 폴리펩타이드 전달용 조성물

Country Status (4)

Country Link
US (1) US20210309763A1 (ko)
EP (1) EP3838924A4 (ko)
KR (1) KR102388028B1 (ko)
CN (1) CN112513098A (ko)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116462202A (zh) * 2023-03-21 2023-07-21 东沃同泰(凤城)生物工程有限公司 一种羧酸修饰二氧化硅气凝胶及其制备方法和应用、药物递送体系

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003106589A1 (en) * 2002-06-13 2003-12-24 Lyotropic Therapeutics, Inc. A nanoporous particle with a retained target
KR101466933B1 (ko) * 2006-07-11 2014-12-01 큐피에스 엘엘씨 펩타이드의 지속 방출 전달을 위한 의약 조성물
EP3173074A4 (en) * 2014-07-22 2018-03-07 Lemonex Inc. Composition for delivering bioactive material or protein, and use thereof
SG11201706562QA (en) * 2015-02-13 2017-09-28 Agency Science Tech & Res NON-MEMBRANE DISRUPTIVE p53 ACTIVATING STAPLED PEPTIDES
WO2017018595A1 (ko) * 2015-07-28 2017-02-02 동국대학교 산학협력단 이중 스테이플화된 펩타이드 및 이의 용도
KR102478884B1 (ko) 2017-03-08 2022-12-20 동국대학교 산학협력단 안정화된 3(10)-helix 구조를 갖는 펩타이드 제조방법

Also Published As

Publication number Publication date
KR102388028B1 (ko) 2022-04-20
EP3838924A2 (en) 2021-06-23
US20210309763A1 (en) 2021-10-07
CN112513098A (zh) 2021-03-16
EP3838924A4 (en) 2022-06-22
KR20200014708A (ko) 2020-02-11

Similar Documents

Publication Publication Date Title
IL284185A (en) Preparations for reducing DRG-specific transgene expression
EP4125815A4 (en) THERAPEUTIC COMPOSITIONS
GB201911800D0 (en) Antiflouling Composition
GB201820878D0 (en) Composition
GB201811100D0 (en) Composition
GB201810492D0 (en) Composition
GB201910650D0 (en) Composition
PL3606505T3 (pl) Kompozycja do podawania donosowego
GB201804434D0 (en) Composition
IL271154B1 (en) Compounds and preparations for inducing cartilage formation
GB201909924D0 (en) Composition
GB201901161D0 (en) Composition
GB201818827D0 (en) Composition
KR102388028B9 (ko) 폴리펩타이드 전달용 조성물
GB201919180D0 (en) New composition of matter
GB201913701D0 (en) Composition of matter
GB201819861D0 (en) Composition
GB201815032D0 (en) Composition
GB201809123D0 (en) Composition
GB201801596D0 (en) Composition
IL263336B (en) Compounds for the treatment of symphysiolysis
GB201913398D0 (en) Composition
GB201806819D0 (en) Compositions for active immunotherapy
GB201820082D0 (en) Composition
GB201818567D0 (en) Composition

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
AMND Amendment
E601 Decision to refuse application
X091 Application refused [patent]
AMND Amendment
E902 Notification of reason for refusal
AMND Amendment
X701 Decision to grant (after re-examination)
G170 Re-publication after modification of scope of protection [patent]